We are live on !
Find out more
Sofinnova Investments Portfolio holdings
AUM
$1.93B
Turnover
49.43%
1-Year Est. Return
134.74%
This Fund
S&P 500
This Quarter Est. Return
+23%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
-$697M
(-26%)
Cap. Flow
-$415M
Cap. Flow % of AUM
Cap. Flow %
-21.46%
Top 10 Holdings %
Top 10 Hldgs %
57.89%
Holding
87
New
13
Increased
14
Reduced
17
Closed
30
Avg Time Held
Equity + Options
1.5
years
Top 10 Avg Time Held
Equity + Options
1.3
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
1.4
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genmab
GMAB
|
+$87.5M |
| 2 |
Seaport Therapeutics
SPTX
|
+$62.7M |
| 3 |
Gilead Sciences
GILD
|
+$45.2M |
| 4 |
AnaptysBio
ANAB
|
+$14.9M |
| 5 |
Abbott
ABT
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$89.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$63.8M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$51M |
| 4 |
United Therapeutics
UTHR
|
+$47.1M |
| 5 |
Biogen
BIIB
|
+$42.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.78% |
| 2 | Miscellaneous | 3.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
BioMarin Pharmaceuticals
BMRN
$10.8B
| $20.5M | 1.06% |
358,568
-423,414
| -54% | -$23.2M |
2025 Q4
2 quarters
|
|
27
Veradermics Inc
MANE
$5.74B
| $18.3M | 0.95% |
148,993
+75,678
| +103% | +$7.09M |
2026 Q1
1 quarter
|
|
28
Alcon
ALC
$33.8B
| $17.2M | 0.89% |
255,824
-474,148
| -65% | -$33.2M |
2025 Q4
2 quarters
|
|
29
Insmed
INSM
$20.4B
| $16.9M | 0.87% |
158,398
-187,677
| -54% | -$22.7M |
2024 Q2
8 quarters
|
|
30
CALL
Ultragenyx Pharmaceutical
RARE
$1.59B
| $16.7M | 0.86% |
500,000
+150,000
| +43% | +$3.73M |
2026 Q1
1 quarter
|
|
31
CALL
Intuitive Surgical
ISRG
$160B
| $15.9M | 0.82% |
+40,000
| New | +$17.5M |
2026 Q2
0 quarters
|
|
32
CALL
Globus Medical
GMED
$11B
| $15.8M | 0.82% |
+200,000
| New | +$17M |
2026 Q2
0 quarters
|
|
33
Edgewise Therapeutics
EWTX
$4.25B
| $15.5M | 0.8% |
380,923
-5,575
| -1% | -$192K |
2024 Q2
8 quarters
|
|
34
PUT
Exelixis
EXEL
$16.1B
| $13.8M | 0.72% |
254,200
+2,700
| +1% | +$131K |
2026 Q1
1 quarter
|
|
35
Nurix Therapeutics
NRIX
$2.79B
| $12.7M | 0.66% |
+524,098
| New | +$8.93M |
2026 Q2
0 quarters
|
|
36
Design Therapeutics
DSGN
$647M
| $12.5M | 0.65% |
+865,135
| New | +$10.8M |
2026 Q2
0 quarters
|
|
37
Definium Therapeutics
DFTX
$4.79B
| $12M | 0.62% |
255,903
-88,263
| -26% | -$2.18M |
2026 Q1
1 quarter
|
|
38
First Tracks Biotherapeutics
TRAX
$1.55B
| $11.4M | 0.59% |
+565,199
| New | +$10.6M |
2026 Q2
0 quarters
|
|
|
39
Abbott
ABT
$181B
| $11.2M | 0.58% |
+122,998
| New | +$11.2M |
2026 Q2
0 quarters
|
|
40
Disc Medicine
IRON
$3.45B
| $10.7M | 0.55% |
146,239
+67,919
| +87% | +$4.67M |
2024 Q1
9 quarters
|
|
41
Tenax Therapeutics
TENX
$61.4M
| $7.28M | 0.38% |
500,039
+395,639
| +379% | +$5.05M |
2026 Q1
1 quarter
|
|
42
Sionna Therapeutics
SION
$167M
| $6.35M | 0.33% |
+144,432
| New | +$5.78M |
2026 Q2
0 quarters
|
|
43
Absci
ABSI
$1.62B
| $3.91M | 0.2% |
+337,400
| New | +$1.9M |
2026 Q2
0 quarters
|
|
44
Mirum Pharmaceuticals
MIRM
$5.41B
| $3.23M | 0.17% |
27,591
| – | – |
2025 Q4
2 quarters
|
|
45
Jade Biosciences
JBIO
$922M
| $2.39M | 0.12% |
107,391
| – | – |
2021 Q2
20 quarters
|
|
46
Savara
SVRA
$929M
| $2.25M | 0.12% |
364,763
| – | – |
2023 Q2
12 quarters
|
|
47
Praxis Precision Medicines
PRAX
$7.47B
| $2.16M | 0.11% |
6,440
-57,240
| -90% | -$18.1M |
2025 Q1
5 quarters
|
|
48
Septerna Inc
SEPN
$1.93B
| $1.59M | 0.08% |
47,506
| – | – |
2026 Q1
1 quarter
|
|
49
OnKure Therapeutics
OKUR
$100M
| $1.47M | 0.08% |
321,692
+179,992
| +127% | +$772K |
2026 Q1
1 quarter
|
|
50
Sagimet Biosciences
SGMT
$678M
| $1.29M | 0.07% |
+166,667
| New | +$1.13M |
2026 Q2
0 quarters
|
|
Similar funds
TCM
Sofinnova Investments's Q2 2026 Portfolio in Review
As of Q2 2026, Sofinnova Investments held 87 positions worth $1.93B, down 26% from $2.63B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Sofinnova Investments withdrew a net $415M in Q2 2026, closing 30 positions and reducing 17 holdings. Its most notable exit was AstraZeneca, an estimated $89.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 76% a quarter earlier, followed by Miscellaneous.
Against the trend, Sofinnova Investments opened a new position in Seaport Therapeutics worth $77.4M.
- Sofinnova Investments's largest Q2 2026 buy was Seaport Therapeutics: 3,564,871 shares worth $77.4M.
- Sofinnova Investments added most to Genmab in Q2 2026, an estimated $87.5M increase.
- Sofinnova Investments's biggest Q2 2026 reduction was Bristol-Myers Squibb, cutting an estimated $63.8M.
- Sofinnova Investments fully exited AstraZeneca in Q2 2026, selling an estimated $89.9M.
- Sofinnova Investments's ten largest holdings make up 58% of its $1.93B portfolio in Q2 2026.
- Sofinnova Investments opened 13 new positions and closed 30 in Q2 2026.
- Sofinnova Investments's portfolio value fell 26% quarter-over-quarter to $1.93B.
Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.